US › Healthcare

Autolus Therapeutics Ltd (AUTL)

US · Healthcare · Biotechnology

$1.95+7.14%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$26.2M
Revenue YoY
+191.9%
Net profit
$-71.6M
Profit YoY
-2.0%
EPS
$-0.27
EPS estimate
$-0.26
Net margin
-273.1%

EPS came in at -0.27 against a street estimate of -0.26 — a miss of 3.8%.

Key statistics

Market cap
$484.4M
Forward P/E
0.0
P/B
3.67
Book value
$5.91
EPS (TTM)
$-1.09
52-week high
$2.52
52-week low
$1.18
50-day MA
$1.57
200-day MA
$1.53
Beta
2.00

Analyst view

Analysts rate Autolus Therapeutics Ltd a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $8.55.

Shareholding

Insiders
18.08%
Institutions
64.18%

Largest institutional holders

FundStake
Mak Capital One LLC12.63%
Blackstone Inc7.70%
Syncona Portfolio Ltd.6.25%
Armistice Capital, LLC5.94%
Polygon Management Ltd3.57%
Schroder Investment Management Group3.57%
Frazier Life Sciences Management, L.P.1.67%
BNP Paribas Investment Partners SA1.26%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Autolus Therapeutics Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.